scholarly journals RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES

2019 ◽  
Vol 22 ◽  
pp. S389 ◽  
Author(s):  
N. Li ◽  
A. Bullement ◽  
S. McMordie ◽  
A.J. Hatswell ◽  
K. Wilson
Sign in / Sign up

Export Citation Format

Share Document